CFL2

Across TCGA pan-cancer cohorts, CFL2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CFL2 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CFL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CFL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where CFL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.921	1.000	.011	11	view →
PDAC	DFS	Tertile	All	0.855	0.690	.018	10	view →
GBM	DFS	Quartile	All	0.218	0.573	.007	5	view →
UCEC	OS	Quartile	II,III,IV	0.500	1.000	.035	4	view →
CCRCC	OS	Median	III,IV	0.910	0.715	.025	3	view →
LUAD	DFS	Median	III,IV	0.305	0.690	.032	2	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CFL2–LSCC (OS)

Open the LSCC breakdown →